×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
DBV Technologies Posts Wider 1Q Loss, Reports Going Concern Doubts
MarketWatch
By Mary de Wet DBV Technologies reported a wider loss in its first quarter and said there is doubt about the company's ability to continue...
8 hours ago
DBV Technologies Reports First Quarter 2024 Financial Results and Business Update
GlobeNewswire
Montrouge, France, May 7, 2024 DBV Technologies Reports First Quarter 2024 Financial Results and Business Update VITESSE enrollment on track...
9 hours ago
DBV Technologies Reports Q1 2024 Financial Results Amidst Progress and Challenges
GuruFocus
Operating Income: $1.4 million for Q1 2024, down from $2.2 million in Q1 2023.Net Loss: Increased to $27.3 million in Q1 2024 from $20.6...
5 hours ago
Has DBV Technologies (DBVT) Outpaced Other Medical Stocks This Year?
Yahoo
Here is how DBV Technologies S.A. (DBVT) and Chinook Therapeutics (KDNY) have performed compared to their sector so far this year.
1 day ago
Food allergy biotech DBV is running out of cash, with phase 3 trials underway
Fierce Biotech
DBV Technologies, a French biotech working on a treatment for food allergies, says it's running out of cash.
1 month ago
DBV Technologies (NASDAQ:DBVT) Receives New Coverage from Analysts at StockNews.com
MarketBeat
StockNews.com assumed coverage on shares of DBV Technologies in a research report on Monday. They issued a "hold" rating for the company.
1 day ago
Shareholders in DBV Technologies (EPA:DBV) have lost 90%, as stock drops 17% this past week
Simply Wall Street
Shareholders in DBV Technologies (EPA:DBV) have lost 90%, as stock drops 17% this past week ... We're definitely into long term investing, but...
2 months ago
DBV Announces Data Presentations for EPIT at the European Academy of Allergy and Clinical Immunology (EAACI ...
Yahoo Life UK
DBV Announces Data Presentations for EPIT TM at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2014 BAGNEUX,...
12 hours ago
DBV Technologies to Participate in Upcoming AAAAI 2024 Congress
GlobeNewswire
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 –NASDAQ: DBVT), a clinical-stage biopharmaceutical company focused on treatments for food...
2 months ago
DBV Technologies S.A. (EPA:DBV) Just Reported Earnings, And Analysts Cut Their Target Price
Simply Wall Street
DBV Technologies. DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous...
1 month ago